Marked leukocytosis in response to estramustine phosphate in a hormone-refractory prostate cancer patient

Case report

(1772) Views  (601) Full article downloads

Author: Tatsuo Morita

Published Date April 2010 Volume 2010:3 Pages 39 - 41

DOI: http://dx.doi.org/10.2147/IMCRJ.S9441

Tatsuo Morita

Department of Urology, Jichi Medical University, Tochigi, Japan

Abstract: A 67-year-old man was refered to our institution with a complaint of elevated serum prostate-specific antigen (PSA) level (54 ng/mL). Diagnosis was adenocarcinoma of the prostate with a Gleason score of 9, with bone metastasis (stageD2). He was treated with maximal androgen blockade followed by estramustine phosphate (EMP) because of the progression to hormone-refractory prostate cancer (HRPC). Leukocytosis over 20000/μL was repeatedly observed at each administration of EMP. This is the first case report of leukocytosis in response to EMP in an HRPC patient. The present case suggests that EMP could modulate leukocyte differentiation in HRPC patients.

Keywords: leukocytosis, neutrophilia, estramustine phosphate, hormone-refractory prostate cancer